1.1 	A bill for an act
1.2 	relating to public safety; modifying the schedules of controlled substances;
1.3 	amending Minnesota Statutes 2018, section 152.02, subdivisions 2, 3, 6.
1.4 	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.5 	Section 1. Minnesota Statutes 2018, section 152.02, subdivision 2, is amended to read:
1.6 		Subd. 2.Schedule I. (a) Schedule I consists of the substances listed in this subdivision.
1.7 	(b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the 
1.8 	following substances, including their analogs, isomers, esters, ethers, salts, and salts of 
1.9 	isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters, ethers, 
1.10 	and salts is possible:
1.11 	(1) acetylmethadol;
1.12 	(2) allylprodine;
1.13 	(3) alphacetylmethadol (except levo-alphacetylmethadol, also known as levomethadyl 
1.14 	acetate);
1.15 	(4) alphameprodine;
1.16 	(5) alphamethadol;
1.17 	(6) alpha-methylfentanyl benzethidine;
1.18 	(7) betacetylmethadol;
1.19 	(8) betameprodine;
1.20 	(9) betamethadol;
2.1 	(10) betaprodine;
2.2 	(11) clonitazene;
2.3 	(12) dextromoramide;
2.4 	(13) diampromide;
2.5 	(14) diethyliambutene;
2.6 	(15) difenoxin;
2.7 	(16) dimenoxadol;
2.8 	(17) dimepheptanol;
2.9 	(18) dimethyliambutene;
2.10 	(19) dioxaphetyl butyrate;
2.11 	(20) dipipanone;
2.12 	(21) ethylmethylthiambutene;
2.13 	(22) etonitazene;
2.14 	(23) etoxeridine;
2.15 	(24) furethidine;
2.16 	(25) hydroxypethidine;
2.17 	(26) ketobemidone;
2.18 	(27) levomoramide;
2.19 	(28) levophenacylmorphan;
2.20 	(29) 3-methylfentanyl;
2.21 	(30) acetyl-alpha-methylfentanyl;
2.22 	(31) alpha-methylthiofentanyl;
2.23 	(32) benzylfentanyl beta-hydroxyfentanyl;
2.24 	(33) beta-hydroxy-3-methylfentanyl;
2.25 	(34) 3-methylthiofentanyl;
2.26 	(35) thenylfentanyl;
2.27 	(36) thiofentanyl;
3.1 	(37) para-fluorofentanyl;
3.2 	(38) morpheridine;
3.3 	(39) 1-methyl-4-phenyl-4-propionoxypiperidine;
3.4 	(40) noracymethadol;
3.5 	(41) norlevorphanol;
3.6 	(42) normethadone;
3.7 	(43) norpipanone;
3.8 	(44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
3.9 	(45) phenadoxone;
3.10 	(46) phenampromide;
3.11 	(47) phenomorphan;
3.12 	(48) phenoperidine;
3.13 	(49) piritramide;
3.14 	(50) proheptazine;
3.15 	(51) properidine;
3.16 	(52) propiram;
3.17 	(53) racemoramide;
3.18 	(54) tilidine;
3.19 	(55) trimeperidine;
3.20 	(56) N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl);
3.21 	(57) 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-
3.22 	methylbenzamide(U47700);
3.23 	(58) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide(furanylfentanyl); 
3.24 	and
3.25 	(59) 4-(4-bromophenyl)-4-dimethylamino-1-phenethylcyclohexanol (bromadol).;
3.26 	(60) N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide (Cyclopropryl 
3.27 	fentanyl);
3.28 	(61) N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide) (butyryl fentanyl);
4.1 	(62) 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine) (MT-45);
4.2 	(63) N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide (cyclopentyl 
4.3 	fentanyl);
4.4 	(64) N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide (isobutyryl fentanyl);
4.5 	(65) N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide (valeryl fentanyl);
4.6 	(66) N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide 
4.7 	(para-chloroisobutyryl fentanyl);
4.8 	(67) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide (para-fluorobutyryl 
4.9 	fentanyl);
4.10 	(68) N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide 
4.11 	(para-methoxybutyryl fentanyl);
4.12 	(69) N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide (ocfentanil);
4.13 	(70) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide (4-fluoroisobutyryl 
4.14 	fentanyl or para-fluoroisobutyryl fentanyl);
4.15 	(71) N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryl fentanyl or 
4.16 	acryloylfentanyl);
4.17 	(72) 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (methoxyacetyl 
4.18 	fentanyl);
4.19 	(73) N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (ortho-fluorofentanyl 
4.20 	or 2-fluorofentanyl);
4.21 	(74) N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide 
4.22 	(tetrahydrofuranyl fentanyl); and
4.23 	(75) Fentanyl-related substances, their isomers, esters, ethers, salts and salts of isomers, 
4.24 	esters and ethers, meaning any substance not otherwise listed under another federal 
4.25 	Administration Controlled Substance Code Number or not otherwise listed in this section, 
4.26 	and for which no exemption or approval is in effect under section 505 of the Federal Food, 
4.27 	Drug, and Cosmetic Act, United States Code , title 21, section 355, that is structurally related 
4.28 	to fentanyl by one or more of the following modifications:
4.29 	(i) replacement of the phenyl portion of the phenethyl group by any monocycle, whether 
4.30 	or not further substituted in or on the monocycle;
5.1 	(ii) substitution in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl, halo, 
5.2 	haloalkyl, amino, or nitro groups;
5.3 	(iii) substitution in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester, ether, 
5.4 	hydroxyl, halo, haloalkyl, amino, or nitro groups;
5.5 	(iv) replacement of the aniline ring with any aromatic monocycle whether or not further 
5.6 	substituted in or on the aromatic monocycle; or
5.7 	(v) replacement of the N-propionyl group by another acyl group.
5.8 	(c) Opium derivatives. Any of the following substances, their analogs, salts, isomers, 
5.9 	and salts of isomers, unless specifically excepted or unless listed in another schedule, 
5.10 	whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
5.11 	(1) acetorphine;
5.12 	(2) acetyldihydrocodeine;
5.13 	(3) benzylmorphine;
5.14 	(4) codeine methylbromide;
5.15 	(5) codeine-n-oxide;
5.16 	(6) cyprenorphine;
5.17 	(7) desomorphine;
5.18 	(8) dihydromorphine;
5.19 	(9) drotebanol;
5.20 	(10) etorphine;
5.21 	(11) heroin;
5.22 	(12) hydromorphinol;
5.23 	(13) methyldesorphine;
5.24 	(14) methyldihydromorphine;
5.25 	(15) morphine methylbromide;
5.26 	(16) morphine methylsulfonate;
5.27 	(17) morphine-n-oxide;
5.28 	(18) myrophine;
6.1 	(19) nicocodeine;
6.2 	(20) nicomorphine;
6.3 	(21) normorphine;
6.4 	(22) pholcodine; and
6.5 	(23) thebacon.
6.6 	(d) Hallucinogens. Any material, compound, mixture or preparation which contains any 
6.7 	quantity of the following substances, their analogs, salts, isomers (whether optical, positional, 
6.8 	or geometric), and salts of isomers, unless specifically excepted or unless listed in another 
6.9 	schedule, whenever the existence of the analogs, salts, isomers, and salts of isomers is 
6.10 	possible:
6.11 	(1) methylenedioxy amphetamine;
6.12 	(2) methylenedioxymethamphetamine;
6.13 	(3) methylenedioxy-N-ethylamphetamine (MDEA);
6.14 	(4) n-hydroxy-methylenedioxyamphetamine;
6.15 	(5) 4-bromo-2,5-dimethoxyamphetamine (DOB);
6.16 	(6) 2,5-dimethoxyamphetamine (2,5-DMA);
6.17 	(7) 4-methoxyamphetamine;
6.18 	(8) 5-methoxy-3, 4-methylenedioxyamphetamine;
6.19 	(9) alpha-ethyltryptamine;
6.20 	(10) bufotenine;
6.21 	(11) diethyltryptamine;
6.22 	(12) dimethyltryptamine;
6.23 	(13) 3,4,5-trimethoxyamphetamine;
6.24 	(14) 4-methyl-2, 5-dimethoxyamphetamine (DOM);
6.25 	(15) ibogaine;
6.26 	(16) lysergic acid diethylamide (LSD);
6.27 	(17) mescaline;
6.28 	(18) parahexyl;
7.1 	(19) N-ethyl-3-piperidyl benzilate;
7.2 	(20) N-methyl-3-piperidyl benzilate;
7.3 	(21) psilocybin;
7.4 	(22) psilocyn;
7.5 	(23) tenocyclidine (TPCP or TCP);
7.6 	(24) N-ethyl-1-phenyl-cyclohexylamine (PCE);
7.7 	(25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy);
7.8 	(26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);
7.9 	(27) 4-chloro-2,5-dimethoxyamphetamine (DOC);
7.10 	(28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);
7.11 	(29) 4-iodo-2,5-dimethoxyamphetamine (DOI);
7.12 	(30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);
7.13 	(31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);
7.14 	(32) 4-methyl-2,5-dimethoxyphenethylamine (2C-D);
7.15 	(33) 4-ethyl-2,5-dimethoxyphenethylamine (2C-E);
7.16 	(34) 4-iodo-2,5-dimethoxyphenethylamine (2C-I);
7.17 	(35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);
7.18 	(36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);
7.19 	(37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);
7.20 	(38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine 
7.21 	(2-CB-FLY);
7.22 	(39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);
7.23 	(40) alpha-methyltryptamine (AMT);
7.24 	(41) N,N-diisopropyltryptamine (DiPT);
7.25 	(42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);
7.26 	(43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);
7.27 	(44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);
8.1 	(45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);
8.2 	(46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);
8.3 	(47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
8.4 	(48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);
8.5 	(49) 5-methoxy-α-methyltryptamine (5-MeO-AMT);
8.6 	(50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
8.7 	(51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);
8.8 	(52) 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT);
8.9 	(53) 5-methoxy-α-ethyltryptamine (5-MeO-AET);
8.10 	(54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);
8.11 	(55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);
8.12 	(56) 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT);
8.13 	(57) methoxetamine (MXE);
8.14 	(58) 5-iodo-2-aminoindane (5-IAI);
8.15 	(59) 5,6-methylenedioxy-2-aminoindane (MDAI);
8.16 	(60) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe);
8.17 	(61) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe);
8.18 	(62) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe);
8.19 	(63) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
8.20 	(64) 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2);
8.21 	(65) N,N-Dipropyltryptamine (DPT);
8.22 	(66) 3-[1-(Piperidin-1-yl)cyclohexyl]phenol (3-HO-PCP);
8.23 	(67) N-ethyl-1-(3-methoxyphenyl)cyclohexanamine (3-MeO-PCE);
8.24 	(68) 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo);
8.25 	(69) 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine (methoxydine, 4-MeO-PCP);
8.26 	(70) 2-(2-Chlorophenyl)-2-(ethylamino)cyclohexan-1-one (N-Ethylnorketamine, 
8.27 	ethketamine, NENK);
9.1 	(71) methylenedioxy-N,N-dimethylamphetamine (MDDMA);
9.2 	(72) 3-(2-Ethyl(methyl)aminoethyl)-1H-indol-4-yl (4-AcO-MET); and
9.3 	(73) 2-Phenyl-2-(methylamino)cyclohexanone (deschloroketamine).
9.4 	(e) Peyote. All parts of the plant presently classified botanically as Lophophora williamsii 
9.5 	Lemaire, whether growing or not, the seeds thereof, any extract from any part of the plant, 
9.6 	and every compound, manufacture, salts, derivative, mixture, or preparation of the plant, 
9.7 	its seeds or extracts. The listing of peyote as a controlled substance in Schedule I does not 
9.8 	apply to the nondrug use of peyote in bona fide religious ceremonies of the American Indian 
9.9 	Church, and members of the American Indian Church are exempt from registration. Any 
9.10 	person who manufactures peyote for or distributes peyote to the American Indian Church, 
9.11 	however, is required to obtain federal registration annually and to comply with all other 
9.12 	requirements of law.
9.13 	(f) Central nervous system depressants. Unless specifically excepted or unless listed in 
9.14 	another schedule, any material compound, mixture, or preparation which contains any 
9.15 	quantity of the following substances, their analogs, salts, isomers, and salts of isomers 
9.16 	whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
9.17 	(1) mecloqualone;
9.18 	(2) methaqualone;
9.19 	(3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;
9.20 	(4) flunitrazepam; and
9.21 	(5) 2-(2-Methoxyphenyl)-2-(methylamino)cyclohexanone (2-MeO-2-deschloroketamine, 
9.22 	methoxyketamine).;
9.23 	(6) tianeptine;
9.24 	(7) clonazolam;
9.25 	(8) etizolam;
9.26 	(9) flubromazolam; and
9.27 	(10) flubromazepam.
9.28 	(g) Stimulants. Unless specifically excepted or unless listed in another schedule, any 
9.29 	material compound, mixture, or preparation which contains any quantity of the following 
9.30 	substances, their analogs, salts, isomers, and salts of isomers whenever the existence of the 
9.31 	analogs, salts, isomers, and salts of isomers is possible:
10.1 	(1) aminorex;
10.2 	(2) cathinone;
10.3 	(3) fenethylline;
10.4 	(4) methcathinone;
10.5 	(5) methylaminorex;
10.6 	(6) N,N-dimethylamphetamine;
10.7 	(7) N-benzylpiperazine (BZP);
10.8 	(8) methylmethcathinone (mephedrone);
10.9 	(9) 3,4-methylenedioxy-N-methylcathinone (methylone);
10.10 	(10) methoxymethcathinone (methedrone);
10.11 	(11) methylenedioxypyrovalerone (MDPV);
10.12 	(12) 3-fluoro-N-methylcathinone (3-FMC);
10.13 	(13) methylethcathinone (MEC);
10.14 	(14) 1-benzofuran-6-ylpropan-2-amine (6-APB);
10.15 	(15) dimethylmethcathinone (DMMC);
10.16 	(16) fluoroamphetamine;
10.17 	(17) fluoromethamphetamine;
10.18 	(18) α-methylaminobutyrophenone (MABP or buphedrone);
10.19 	(19) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone);
10.20 	(20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);
10.21 	(21) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one (naphthylpyrovalerone or 
10.22 	naphyrone);
10.23 	(22) (alpha-pyrrolidinopentiophenone (alpha-PVP);
10.24 	(23) (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone (4-Me-PHP or MPHP);
10.25 	(24) 2-(1-pyrrolidinyl)-hexanophenone (Alpha-PHP);
10.26 	(25) 4-methyl-N-ethylcathinone (4-MEC);
10.27 	(26) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP);
11.1 	(27) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
11.2 	(28) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone);
11.3 	(29) 4-fluoro-N-methylcathinone (4-FMC);
11.4 	(30) 3,4-methylenedioxy-N-ethylcathinone (ethylone);
11.5 	(31) alpha-pyrrolidinobutiophenone (α-PBP);
11.6 	(32) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB);
11.7 	(33) 1-phenyl-2-(1-pyrrolidinyl)-1-heptanone (PV8);
11.8 	(34) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB);
11.9 	(35) 4-methyl-alpha-ethylaminopentiophenone (4-MEAPP);
11.10 	(36) 4'-chloro-alpha-pyrrolidinopropiophenone (4'-chloro-PPP);
11.11 	(37) 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)butan-1-one (dibutylone, bk-DMBDB);
11.12 	(38) 1-(3-chlorophenyl) piperazine (meta-chlorophenylpiperazine or mCPP); and
11.13 	(39) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one (N-ethylpentylone, ephylone); 
11.14 	and
11.15 	(40) any other substance, except bupropion or compounds listed under a different 
11.16 	schedule, that is structurally derived from 2-aminopropan-1-one by substitution at the 
11.17 	1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the 
11.18 	compound is further modified in any of the following ways:
11.19 	(i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, 
11.20 	haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring 
11.21 	system by one or more other univalent substituents;
11.22 	(ii) by substitution at the 3-position with an acyclic alkyl substituent;
11.23 	(iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or 
11.24 	methoxybenzyl groups; or
11.25 	(iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.
11.26 	(h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless specifically 
11.27 	excepted or unless listed in another schedule, any natural or synthetic material, compound, 
11.28 	mixture, or preparation that contains any quantity of the following substances, their analogs, 
11.29 	isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence 
11.30 	of the isomers, esters, ethers, or salts is possible:
12.1 	(1) marijuana;
12.2 	(2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, synthetic 
12.3 	equivalents of the substances contained in the cannabis plant or in the resinous extractives 
12.4 	of the plant, or synthetic substances with similar chemical structure and pharmacological 
12.5 	activity to those substances contained in the plant or resinous extract, including, but not 
12.6 	limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans tetrahydrocannabinol, and 3,4 
12.7 	cis or trans tetrahydrocannabinol;
12.8 	(3) synthetic cannabinoids, including the following substances:
12.9 	(i) Naphthoylindoles, which are any compounds containing a 3-(1-napthoyl)indole 
12.10 	structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, 
12.11 	alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
12.12 	2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any 
12.13 	extent and whether or not substituted in the naphthyl ring to any extent. Examples of 
12.14 	naphthoylindoles include, but are not limited to:
12.15 	(A) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);
12.16 	(B) 1-Butyl-3-(1-naphthoyl)indole (JWH-073);
12.17 	(C) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);
12.18 	(D) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);
12.19 	(E) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);
12.20 	(F) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);
12.21 	(G) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);
12.22 	(H) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);
12.23 	(I) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);
12.24 	(J) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).
12.25 	(ii) Napthylmethylindoles, which are any compounds containing a 
12.26 	1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the 
12.27 	indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
12.28 	1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further 
12.29 	substituted in the indole ring to any extent and whether or not substituted in the naphthyl 
12.30 	ring to any extent. Examples of naphthylmethylindoles include, but are not limited to:
12.31 	(A) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);
13.1 	(B) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane (JWH-184).
13.2 	(iii) Naphthoylpyrroles, which are any compounds containing a 3-(1-naphthoyl)pyrrole 
13.3 	structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, 
13.4 	alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
13.5 	2-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any 
13.6 	extent, whether or not substituted in the naphthyl ring to any extent. Examples of 
13.7 	naphthoylpyrroles include, but are not limited to, 
13.8 	(5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).
13.9 	(iv) Naphthylmethylindenes, which are any compounds containing a naphthylideneindene 
13.10 	structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, 
13.11 	cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
13.12 	2-(4-morpholinyl)ethyl group whether or not further substituted in the indene ring to any 
13.13 	extent, whether or not substituted in the naphthyl ring to any extent. Examples of 
13.14 	naphthylemethylindenes include, but are not limited to, 
13.15 	E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).
13.16 	(v) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole 
13.17 	structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, 
13.18 	alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
13.19 	2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any 
13.20 	extent, whether or not substituted in the phenyl ring to any extent. Examples of 
13.21 	phenylacetylindoles include, but are not limited to:
13.22 	(A) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);
13.23 	(B) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);
13.24 	(C) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);
13.25 	(D) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).
13.26 	(vi) Cyclohexylphenols, which are compounds containing a 
13.27 	2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic 
13.28 	ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
13.29 	1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not substituted 
13.30 	in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include, but are not 
13.31 	limited to:
13.32 	(A) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);
14.1 	(B) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol 
14.2 	(Cannabicyclohexanol or CP 47,497 C8 homologue);
14.3 	(C) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl] 
14.4 	-phenol (CP 55,940).
14.5 	(vii) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole structure 
14.6 	with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, 
14.7 	cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
14.8 	2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any 
14.9 	extent and whether or not substituted in the phenyl ring to any extent. Examples of 
14.10 	benzoylindoles include, but are not limited to:
14.11 	(A) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);
14.12 	(B) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);
14.13 	(C) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone (WIN 
14.14 	48,098 or Pravadoline).
14.15 	(viii) Others specifically named:
14.16 	(A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) 
14.17 	-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);
14.18 	(B) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) 
14.19 	-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);
14.20 	(C) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de] 
14.21 	-1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2);
14.22 	(D) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);
14.23 	(E) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone 
14.24 	(XLR-11);
14.25 	(F) 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide 
14.26 	(AKB-48(APINACA));
14.27 	(G) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide 
14.28 	(5-Fluoro-AKB-48);
14.29 	(H) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);
14.30 	(I) 8-quinolinyl ester-1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5-Fluoro PB-22);
15.1 	(J) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole- 3-carboxamide 
15.2 	(AB-PINACA);
15.3 	(K) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]- 
15.4 	1H-indazole-3-carboxamide (AB-FUBINACA);
15.5 	(L) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H- 
15.6 	indazole-3-carboxamide(AB-CHMINACA);
15.7 	(M) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3- methylbutanoate 
15.8 	(5-fluoro-AMB);
15.9 	(N) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone (THJ-2201);
15.10 	(O) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone) 
15.11 	(FUBIMINA);
15.12 	(P) (7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo 
15.13 	[2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12);
15.14 	(Q) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl) 
15.15 	-1H-indole-3-carboxamide (5-fluoro-ABICA);
15.16 	(R) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl) 
15.17 	-1H-indole-3-carboxamide;
15.18 	(S) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl) 
15.19 	-1H-indazole-3-carboxamide;
15.20 	(T) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido) -3,3-dimethylbutanoate;
15.21 	(U) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1 
15.22 	H-indazole-3-carboxamide (MAB-CHMINACA);
15.23 	(V) N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-pentyl-1H-indazole-3-carboxamide 
15.24 	(ADB-PINACA);
15.25 	(W) methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate (FUB-AMB);
15.26 	(X) N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-1-(cyclohexylmethyl)-1H-Indazole-
15.27 	3-carboxamide. (APP-CHMINACA);
15.28 	(Y) quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FUB-PB-22); and
15.29 	(Z) methyl N-[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]valinate (MMB-CHMICA).
15.30 	(ix) Additional substances specifically named:
16.1 	(A) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1 
16.2 	H-pyrrolo[2,3-B]pyridine-3-carboxamide (5F-CUMYL-P7AICA);
16.3 	(B) 1-(4-cyanobutyl)-N-(2- phenylpropan-2-yl)-1 H-indazole-3-carboxamide 
16.4 	(4-CN-Cumyl-Butinaca);
16.5 	(C) naphthalen-1-yl-1-(5-fluoropentyl)-1-H-indole-3-carboxylate (NM2201; CBL2201);
16.6 	(D) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1 
16.7 	H-indazole-3-carboxamide (5F-ABPINACA);
16.8 	(E) methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate 
16.9 	(MDMB CHMICA);
16.10 	(F) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate 
16.11 	(5F-ADB; 5F-MDMB-PINACA); and
16.12 	(G) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl) 
16.13 	1H-indazole-3-carboxamide (ADB-FUBINACA).
16.14 	(i) A controlled substance analog, to the extent that it is implicitly or explicitly intended 
16.15 	for human consumption.

16.16 	Sec. 2. Minnesota Statutes 2018, section 152.02, subdivision 3, is amended to read:
16.17 		Subd. 3.Schedule II. (a) Schedule II consists of the substances listed in this subdivision.
16.18 	(b) Unless specifically excepted or unless listed in another schedule, any of the following 
16.19 	substances whether produced directly or indirectly by extraction from substances of vegetable 
16.20 	origin or independently by means of chemical synthesis, or by a combination of extraction 
16.21 	and chemical synthesis:
16.22 	(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or 
16.23 	opiate.
16.24 	(i) Excluding:
16.25 	(A) apomorphine;
16.26 	(B) thebaine-derived butorphanol;
16.27 	(C) dextrophan;
16.28 	(D) nalbuphine;
16.29 	(E) nalmefene;
16.30 	(F) naloxegol;
17.1 	(G) naloxone;
17.2 	(H) naltrexone; and
17.3 	(I) their respective salts;
17.4 	(ii) but including the following:
17.5 	(A) opium, in all forms and extracts;
17.6 	(B) codeine;
17.7 	(C) dihydroetorphine;
17.8 	(D) ethylmorphine;
17.9 	(E) etorphine hydrochloride;
17.10 	(F) hydrocodone;
17.11 	(G) hydromorphone;
17.12 	(H) metopon;
17.13 	(I) morphine;
17.14 	(J) oxycodone;
17.15 	(K) oxymorphone;
17.16 	(L) thebaine;
17.17 	(M) oripavine;
17.18 	(2) any salt, compound, derivative, or preparation thereof which is chemically equivalent 
17.19 	or identical with any of the substances referred to in clause (1), except that these substances 
17.20 	shall not include the isoquinoline alkaloids of opium;
17.21 	(3) opium poppy and poppy straw;
17.22 	(4) coca leaves and any salt, cocaine compound, derivative, or preparation of coca leaves 
17.23 	(including cocaine and ecgonine and their salts, isomers, derivatives, and salts of isomers 
17.24 	and derivatives), and any salt, compound, derivative, or preparation thereof which is 
17.25 	chemically equivalent or identical with any of these substances, except that the substances 
17.26 	shall not include decocainized coca leaves or extraction of coca leaves, which extractions 
17.27 	do not contain cocaine or ecgonine;
17.28 	(5) concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid, 
17.29 	or powder form which contains the phenanthrene alkaloids of the opium poppy).
18.1 	(c) Any of the following opiates, including their isomers, esters, ethers, salts, and salts 
18.2 	of isomers, esters and ethers, unless specifically excepted, or unless listed in another schedule, 
18.3 	whenever the existence of such isomers, esters, ethers and salts is possible within the specific 
18.4 	chemical designation:
18.5 	(1) alfentanil;
18.6 	(2) alphaprodine;
18.7 	(3) anileridine;
18.8 	(4) bezitramide;
18.9 	(5) bulk dextropropoxyphene (nondosage forms);
18.10 	(6) carfentanil;
18.11 	(7) dihydrocodeine;
18.12 	(8) dihydromorphinone;
18.13 	(9) diphenoxylate;
18.14 	(10) fentanyl;
18.15 	(11) isomethadone;
18.16 	(12) levo-alpha-acetylmethadol (LAAM);
18.17 	(13) levomethorphan;
18.18 	(14) levorphanol;
18.19 	(15) metazocine;
18.20 	(16) methadone;
18.21 	(17) methadone - intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
18.22 	(18) moramide - intermediate, 2-methyl-3-morpholino-1, 1-diphenyl-propane-carboxylic 
18.23 	acid;
18.24 	(19) pethidine;
18.25 	(20) pethidine - intermediate - a, 4-cyano-1-methyl-4-phenylpiperidine;
18.26 	(21) pethidine - intermediate - b, ethyl-4-phenylpiperidine-4-carboxylate;
18.27 	(22) pethidine - intermediate - c, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
18.28 	(23) phenazocine;
19.1 	(24) piminodine;
19.2 	(25) racemethorphan;
19.3 	(26) racemorphan;
19.4 	(27) remifentanil;
19.5 	(28) sufentanil;
19.6 	(29) tapentadol;
19.7 	(30) 4-Anilino-N-phenethyl-4-piperidine (ANPP).
19.8 	(d) Unless specifically excepted or unless listed in another schedule, any material, 
19.9 	compound, mixture, or preparation which contains any quantity of the following substances 
19.10 	having a stimulant effect on the central nervous system:
19.11 	(1) amphetamine, its salts, optical isomers, and salts of its optical isomers;
19.12 	(2) methamphetamine, its salts, isomers, and salts of its isomers;
19.13 	(3) phenmetrazine and its salts;
19.14 	(4) methylphenidate;
19.15 	(5) lisdexamfetamine.
19.16 	(e) Unless specifically excepted or unless listed in another schedule, any material, 
19.17 	compound, mixture, or preparation which contains any quantity of the following substances 
19.18 	having a depressant effect on the central nervous system, including its salts, isomers, and 
19.19 	salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible 
19.20 	within the specific chemical designation:
19.21 	(1) amobarbital;
19.22 	(2) glutethimide;
19.23 	(3) secobarbital;
19.24 	(4) pentobarbital;
19.25 	(5) phencyclidine;
19.26 	(6) phencyclidine immediate precursors:
19.27 	(i) 1-phenylcyclohexylamine;
19.28 	(ii) 1-piperidinocyclohexanecarbonitrile;
19.29 	(7) phenylacetone.
20.1 	(f) Hallucinogenic substances Cannabinoids:
20.2 	(1) nabilone.;
20.3 	(2) dronabinol [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)] in an oral solution 
20.4 	in a drug product approved for marketing by the United States Food and Drug Administration.

20.5 	Sec. 3. Minnesota Statutes 2018, section 152.02, subdivision 6, is amended to read:
20.6 		Subd. 6.Schedule V; restrictions on methamphetamine precursor drugs. (a) As used 
20.7 	in this subdivision, the following terms have the meanings given:
20.8 	(1) "methamphetamine precursor drug" means any compound, mixture, or preparation 
20.9 	intended for human consumption containing ephedrine or pseudoephedrine as its sole active 
20.10 	ingredient or as one of its active ingredients; and
20.11 	(2) "over-the-counter sale" means a retail sale of a drug or product but does not include 
20.12 	the sale of a drug or product pursuant to the terms of a valid prescription.
20.13 	(b) The following items are listed in Schedule V:
20.14 	(1) any compound, mixture, or preparation containing any of the following limited 
20.15 	quantities of narcotic drugs, which shall include one or more nonnarcotic active medicinal 
20.16 	ingredients in sufficient proportion to confer upon the compound, mixture or preparation 
20.17 	valuable medicinal qualities other than those possessed by the narcotic drug alone:
20.18 	(i) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;
20.19 	(ii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;
20.20 	(iii) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of 
20.21 	atropine sulfate per dosage unit;
20.22 	(iv) not more than 100 milligrams of opium per 100 milliliters or per 100 grams; or
20.23 	(v) not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine 
20.24 	sulfate per dosage unit.
20.25 	(2) Stimulants. Unless specifically exempted or excluded or unless listed in another 
20.26 	schedule, any material, compound, mixture, or preparation that contains any quantity of the 
20.27 	following substance having a stimulant effect on the central nervous system, including its 
20.28 	salts, isomers, and salts of isomers: pyrovalerone.
20.29 	(3) Depressants. Unless specifically exempted or excluded or unless listed in another 
20.30 	schedule, any material, compound, mixture, or preparation that contains any quantity of the 
21.1 	following substance having a depressant effect on the central nervous system, including its 
21.2 	salts, isomers, and salts of isomers:
21.3 	(i) ezogabine;
21.4 	(ii) pregabalin;
21.5 	(iii) lacosamide.; and
21.6 	(iv) gabapentin.
21.7 	(4) Any compound, mixture, or preparation containing ephedrine or pseudoephedrine 
21.8 	as its sole active ingredient or as one of its active ingredients.
21.9 	(5) A drug product in finished dosage formulation that has been approved by the United 
21.10 	States Food and Drug Administration that contains cannabidiol 
21.11 	(2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-l,3-benzenediol) derived 
21.12 	from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.
21.13 	(c) No person may sell in a single over-the-counter sale more than two packages of a 
21.14 	methamphetamine precursor drug or a combination of methamphetamine precursor drugs 
21.15 	or any combination of packages exceeding a total weight of six grams, calculated as the 
21.16 	base.
21.17 	(d) Over-the-counter sales of methamphetamine precursor drugs are limited to:
21.18 	(1) packages containing not more than a total of three grams of one or more 
21.19 	methamphetamine precursor drugs, calculated in terms of ephedrine base or pseudoephedrine 
21.20 	base; or
21.21 	(2) for nonliquid products, sales in blister packs, where each blister contains not more 
21.22 	than two dosage units, or, if the use of blister packs is not technically feasible, sales in unit 
21.23 	dose packets or pouches.
21.24 	(e) A business establishment that offers for sale methamphetamine precursor drugs in 
21.25 	an over-the-counter sale shall ensure that all packages of the drugs are displayed behind a 
21.26 	checkout counter where the public is not permitted and are offered for sale only by a licensed 
21.27 	pharmacist, a registered pharmacy technician, or a pharmacy clerk. The establishment shall 
21.28 	ensure that the person making the sale requires the buyer:
21.29 	(1) to provide photographic identification showing the buyer's date of birth; and
21.30 	(2) to sign a written or electronic document detailing the date of the sale, the name of 
21.31 	the buyer, and the amount of the drug sold.
22.1 	A document described under clause (2) must be retained by the establishment for at least 
22.2 	three years and must at all reasonable times be open to the inspection of any law enforcement 
22.3 	agency.
22.4 	Nothing in this paragraph requires the buyer to obtain a prescription for the drug's 
22.5 	purchase.
22.6 	(f) No person may acquire through over-the-counter sales more than six grams of 
22.7 	methamphetamine precursor drugs, calculated as the base, within a 30-day period.
22.8 	(g) No person may sell in an over-the-counter sale a methamphetamine precursor drug 
22.9 	to a person under the age of 18 years. It is an affirmative defense to a charge under this 
22.10 	paragraph if the defendant proves by a preponderance of the evidence that the defendant 
22.11 	reasonably and in good faith relied on proof of age as described in section 340A.503, 
22.12 	subdivision 6.
22.13 	(h) A person who knowingly violates paragraph (c), (d), (e), (f), or (g) is guilty of a 
22.14 	misdemeanor and may be sentenced to imprisonment for not more than 90 days, or to 
22.15 	payment of a fine of not more than $1,000, or both.
22.16 	(i) An owner, operator, supervisor, or manager of a business establishment that offers 
22.17 	for sale methamphetamine precursor drugs whose employee or agent is convicted of or 
22.18 	charged with violating paragraph (c), (d), (e), (f), or (g) is not subject to the criminal penalties 
22.19 	for violating any of those paragraphs if the person:
22.20 	(1) did not have prior knowledge of, participate in, or direct the employee or agent to 
22.21 	commit the violation; and
22.22 	(2) documents that an employee training program was in place to provide the employee 
22.23 	or agent with information on the state and federal laws and regulations regarding 
22.24 	methamphetamine precursor drugs.
22.25 	(j) Any person employed by a business establishment that offers for sale 
22.26 	methamphetamine precursor drugs who sells such a drug to any person in a suspicious 
22.27 	transaction shall report the transaction to the owner, supervisor, or manager of the 
22.28 	establishment. The owner, supervisor, or manager may report the transaction to local law 
22.29 	enforcement. A person who reports information under this subdivision in good faith is 
22.30 	immune from civil liability relating to the report.
22.31 	(k) Paragraphs (b) to (j) do not apply to:
22.32 	(1) pediatric products labeled pursuant to federal regulation primarily intended for 
22.33 	administration to children under 12 years of age according to label instructions;
23.1 	(2) methamphetamine precursor drugs that are certified by the Board of Pharmacy as 
23.2 	being manufactured in a manner that prevents the drug from being used to manufacture 
23.3 	methamphetamine;
23.4 	(3) methamphetamine precursor drugs in gel capsule or liquid form; or
23.5 	(4) compounds, mixtures, or preparations in powder form where pseudoephedrine 
23.6 	constitutes less than one percent of its total weight and is not its sole active ingredient.
23.7 	(l) The Board of Pharmacy, in consultation with the Department of Public Safety, shall 
23.8 	certify methamphetamine precursor drugs that meet the requirements of paragraph (k), 
23.9 	clause (2), and publish an annual listing of these drugs.
23.10 	(m) Wholesale drug distributors licensed and regulated by the Board of Pharmacy 
23.11 	pursuant to sections 151.42 to 151.51 and registered with and regulated by the United States 
23.12 	Drug Enforcement Administration are exempt from the methamphetamine precursor drug 
23.13 	storage requirements of this section.
23.14 	(n) This section preempts all local ordinances or regulations governing the sale by a 
23.15 	business establishment of over-the-counter products containing ephedrine or 
23.16 	pseudoephedrine. All ordinances enacted prior to the effective date of this act are void.